Biospecifics Technologies (BSTC) Reports Q4 EPS of $0.32
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
BioSpecifics Technologies Corp. Reports First Quarter 2015 Financial Results
May 11, 2015 4:01 PM EDTLYNBROOK, N.Y., May 11, 2015 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics" or the "Company"), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the first quarter ended March 31, 2015 and provided a corporate update.
"We are seeing strong U.S. commercial growth for XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease, which led to our robust financial results for the quarter. Our net... More
